ABSTRACT Resistance to apoptotic is a cancer cell trait which shows a significant part in tumour formation and was a potential target for antitumor therapy. The coumarin molecule isoimperatorin (ISOIM) has anticancer properties in a variety of tumour cells. However, its anticancer properties and molecular pathways in stomach cancer have yet to be discovered. The current work investigated ISOIM's antineoplastic and apoptosis influences on patient BGC823 tumor growth, as well as the molecular pathways that underpin them. MTT assays were used to assess cell growth. Hematoxylin and eosin (H&E), acridine orange or ethidium bromide, stain was used to examine cell morphology. In furthermore, flow cytometry was utilized to assess cell cycle and apoptotic, and western blotting (WB) was employed to investigate the production of apoptosis-associated enzymes. ISOIM markedly decreased cell growth by halting cell cycle during the G2 or M stage and promoted apoptotic through elevating Bcl2 associated X (Bax) production with a concurrent reduction in Bcl2 expression, results in a lower Bcl2/Bax proportion than the control. Furthermore, ISOIM therapy caused cytochrome c to move from mitochondria to its cytosol. In addition, caspase 3 were substantially induced in reaction to ISOIM therapy, implying that apoptotic in BGC823 cells are triggered through the mitochondrial pathway. Overall, the findings of this study suggest that ISOIM can dramatically cause apoptosis in BGC823 cells, and also that ISOIM's proapoptotic processes may be linked to the mitochondrial route.